Audit: QRS - sh-Oligopeptide-4 for Hair Regrowth
Audit conducted on 24/08/2026 04:27 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span. Protocol cells trace to ER lines 306/314/318; time cells to ER lines 143/363/341; all eight monitoring rows to the ER table (ER lines 397–404); cadence to ER line 393; contraindications to ER lines 277–282; interactions to ER lines 257–273. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “no circadian data exist”, “no dose-response study exists”, “No established target”, “theoretical tumour-promotion signal” and the “— conflicted” flags all mirror the ER’s hedging. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Both ⚠️ Conflicted entries (ER lines 149 and 199) retain the “conflicted” flag rather than being flattened; contraindications remain absolute avoid statements. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | [stop_items] come only from the ER’s “Populations who should avoid” list; [caution_items] only from the ER’s interaction bullets. No Benefit- or Risk-Modifying Factor is promoted into a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, NCT numbers, author names or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s deflationary, evidence-first register: rodent consistency stated, human absence stated, delivery problem stated. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Objective and data-driven throughout; the Protocol, Monitoring and Qualitative Assessment cards give the reader concrete, actionable footing despite a negative evidence base. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Cells state what is done and what is unknown (“no dose-response study exists”) rather than issuing orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or advisory constructions; monitoring rows state the marker and the reason it is measured. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instance of “recommended”, “should”, “advised” or equivalent in the QRS body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun appears anywhere in the sheet. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the ER’s own biomarker names and mechanism headings; the At-A-Glance and Protocol panels use plain wording. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Each tier is a single condensed list item, monitoring “why” strings are one clause each, and protocol sub-lines are single clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address anywhere on the sheet. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | An eight-marker baseline panel, tattooed-zone phototrichogram and tumour-marker surveillance presuppose a proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twice-daily overnight application, standardised photography at 4/8/12 months and repeat blood panels assume that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nothing is simplified to a general-population “just try it” framing; the measurement discipline requirement is retained. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance foregrounds the delivery-size problem and the negative human-tissue result — the two facts that matter most to a reader deciding whether to spend money on this ingredient. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “adverse events”, “application-site reactions”, “anti-drug antibodies”, “phototrichogram” — clinical register maintained. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present verbatim (lines 445, 488, 537, 561, 574, 595, 622, 626–628, 732) and the four tier labels appear as “High: “, “Medium: “, “Low: “, “Speculative: “. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every variable named in this checklist is present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 label/value/sub, time_1–3 label/value/sub, benefits_* (4), stop_items, caution_items, risks_* (4), marker_1–8 name/target/why, monitoring_cadence, qualitative_item_1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable template spans website="evidence_review", website="audit" and website="full_review" (lines 423, 426, 439) are untouched, as is the whole <style> block. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped to the QRS is empty. The empty benefit/risk tiers are sub-sections governed by 12.5 / 13.5 (display:none), not by empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard cosmetic approach”, “Best time of day”, “Single versus split dosing” are the ER’s bold labels verbatim (ER lines 306, 314, 318); interaction labels including their “(caution, additive)” / “(monitor)” suffixes are carried through. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Where the ER supplies a bold label it is reused unchanged; the Time-to-effect cell labels derive from ER headings and prose because the ER has no per-cell bold labels for them. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the QRS; the ER’s 🟩/🟥/🟨 and ⚠️ markers were correctly dropped, with “conflicted” carried as plain text. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every discretionary section is condensed to its budget: each benefit/risk tier collapsed to one list item, At-A-Glance at 59 words, three protocol cells and three time cells. Remaining volume is driven by the completeness requirements of 9.2, 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1, before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are repeated in the body except the creation date and model, which are required by 6.3 / 6.4. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: sh_oligopeptide_4_hair_2026-0824-0220_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge in QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0824-0339. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: sh_oligopeptide_4_hair_2026-0824-0220_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “sh-Oligopeptide-4 for Hair Regrowth - Quick Reference Sheet”; canonical_topic contains no characters requiring encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “sh-Oligopeptide-4 for Hair Regrowth”, matching ER frontmatter line 8. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/24/2026”, the correct MM/DD/YYYY rendering of 2026-0824-0339. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching frontmatter line 8. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the title and the template subline; the ER’s “Also known as” line is correctly not reproduced. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all four Conclusion paragraphs (ER lines 434–438) into the decision-relevant core: rodent consistency, absent human data, contrary tissue result, delivery barrier, untested chronic use. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Five claims map to ER lines 434 (rodent consistency), 436 (no controlled study; opposite-direction follicle test; size versus skin barrier) and 438 (“Nothing addresses years of scalp use”). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “angiogenesis”, “ex vivo”, “kDa” and “organ culture” are all avoided in favour of plain wording. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Refers to “the one test on living human scalp follicles” without naming, dating or sizing it. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind appear in the At-A-Glance text. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from the “Populations who should avoid sh-Oligopeptide-4” list at ER lines 275–282. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-list entries are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six discrete <li> elements at lines 564–569. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing em-dash clauses (“— no reproductive toxicity data exist for any route”, “— thymosin β4 and its fragments are prohibited…”) are correctly stripped; no dash-trailing content remains in any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “in remission under five years”, “under World Anti-Doping Agency (WADA) jurisdiction” and “on maintenance immunosuppression” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid list uses no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names six such populations and the section is correspondingly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items come from the interaction bullets at ER lines 257–273. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine ER interaction bullets present; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements at lines 577–585. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER explanatory sentence is dropped; each item is the label plus its drug list and severity tag only. No dashes anywhere in the list. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named examples retained for shampoos (ketoconazole 2%, salicylic acid, coal tar), angiogenic supplements (L-arginine, L-citrulline, beetroot, Ginkgo biloba), opposing supplements (high-dose curcumin, epigallocatechin gallate, resveratrol), retinoids and anticoagulants; the “(caution)”/”(monitor)”/”(additive)” severity tags are preserved throughout. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation; drug examples are already comma-separated. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names nine such interactions and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol bullets at lines 306, 314 and 318. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose and frequency, timing, and split-versus-single dosing are the three bullets that state what is actually done; the remaining ER bullets are modifiers, competing approaches or pharmacology rather than implementation actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated: “0.5–1 mL, once or twice daily” / “1–100 ppm … dry scalp” (ER 306), “Evening, dry scalp” / overnight contact, no circadian data (ER 314), “Twice daily over one dose” / short residence time, no dose-response study (ER 318). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Wound closure within 3 months (ER 143), visible hair change at 3–4 months and fair assessment at 12 months (ER 363, 341) are the only time-anchored outcomes the ER supplies. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | The Medium-tier benefit (accelerated wound closure) is placed first; the two Speculative-tier hair timings follow, ordered by increasing horizon. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated and traceable — e.g. “About 25% of venous ulcer patients reached complete closure at the 0.03% dose” from the ER Magnitude line 143, and “No measurable change by 12 months has no plausible explanation other than non-response” from ER line 341. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER lines 143, 341, 363), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Both populated tiers map to ER lines 133–163. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 539, 542, 545 and 548. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Medium is the bare heading; the four speculative benefits are compressed into one semicolon-separated line with all trial detail, magnitudes and citations dropped. The retained “conflicted” flag is the ER’s own evidence marker, not a qualifier. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain; the ER’s “(Gao et al., 2015)”, “(Dai et al., 2019)” and the 25%-closure magnitude are all absent from the Benefits card. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | [benefits_high] (line 539) and [benefits_low] (line 545) both carry style="display: none" with an HTML comment recording the ER basis; no empty-state text is rendered. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All three populated tiers map to ER lines 185–235. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 597, 600, 603 and 610. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The four Low-tier and three Speculative-tier risks are each reduced to a short noun phrase; the phase 1 percentages, the 1-of-108 antibody counts and the 73-patient ulcer trial detail are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain; the ER’s glosses such as “(a blood protein raised in some surface-tissue cancers)” and “(bacterial cell-wall toxin)” are absent. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | [risks_medium] (line 600) carries style="display: none" with the comment <!-- empty: ER states "No risk reaches Medium" -->; no empty-state text is rendered. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence come from the ER Monitoring Protocol & Defining Success section, lines 391–404. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER table rows are present, with optimal ranges preserved: ferritin, 25-hydroxyvitamin D, TSH, zinc, androgen panel, haemoglobin, squamous cell carcinoma antigen, phototrichogram. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 725 reproduces the ER’s schedule: baseline panel, tumour marker and skin check at 6 and 12 months, photography and hair census at 4, 8 and 12 months then annually (ER line 393). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The five items map one-to-one to the ER’s “Qualitative markers worth tracking” bullets at lines 408–412. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five present: shed volume, scalp visibility, perceived shaft thickness and styling product, scalp comfort, hairline regrowth rate between haircuts. |
Issues 24/08/2026 04:27
Pass rate 100.00%. No issues found.
Issues 24/08/2026 04:19
- 2.15 — Colloquial “lab-made” in At-A-Glance: [at_a_glance] (line 434) opens with “A lab-made copy of a small human protein” where the ER’s Conclusion uses the formal “laboratory-made copy of a small human protein” (ER line 434).
- 4.2 / 4.3 — Key Interaction labels paraphrased: Five [caution_items] (lines 582–585) do not reproduce the ER’s bold labels verbatim — “Medicated shampoos”, “Anticoagulants and antiplatelets”, “Angiogenic or vasodilatory supplements”, “Possibly mechanism-opposing supplements” and “Platelet-rich plasma and exosome injections” against the ER’s “Over-the-counter medicated shampoos”, “Anticoagulants and antiplatelet agents”, “Supplements with additive angiogenic or vasodilatory effects”, “Supplements that plausibly oppose the mechanism” and “Platelet-rich plasma and exosome scalp injections” (ER lines 265–273).
Fixes 24/08/2026 04:19
- 2.15 — Formal wording in At-A-Glance: Replaced the colloquial “A lab-made copy” with the ER’s own formal “A laboratory-made copy” in [at_a_glance]; the section remains at 59 words.
- 4.2 / 4.3 — Key Interaction labels restored verbatim: Restored the five paraphrased [caution_items] labels to the ER’s bold labels — “Anticoagulants and antiplatelet agents”, “Platelet-rich plasma and exosome scalp injections”, “Over-the-counter medicated shampoos”, “Supplements with additive angiogenic or vasodilatory effects” and “Supplements that plausibly oppose the mechanism” — while keeping the named drug lists and the (caution)/(monitor) tags.
Issues 24/08/2026 04:13
- 1.2 / 1.3 — Dropped “plausibly” hedge: The ER bullet “Supplements that plausibly oppose the mechanism (monitor)” (ER line 271), whose body adds “the interaction is theoretical”, is rendered in [caution_items] at QRS line 584 as “Mechanism-opposing supplements (high-dose curcumin, epigallocatechin gallate, resveratrol) (monitor)”, which asserts the opposition as established rather than theoretical.
Fixes 24/08/2026 04:13
- 1.2 / 1.3 — Restored “plausibly” hedge: In [caution_items] (QRS line 584), “Mechanism-opposing supplements (high-dose curcumin, epigallocatechin gallate, resveratrol) (monitor)” was changed to “Possibly mechanism-opposing supplements (…) (monitor)”, restoring the ER’s hedge that the interaction is theoretical.
Issues 24/08/2026 04:04
- 1.3 — Strengthened 12-month claim: [time_3_sub] at line 527 states “No measurable change by 12 months has no explanation other than non-response”, dropping “plausible” from the ER’s “no plausible explanation other than non-response” (ER line 341) and thereby strengthening the claim.
Fixes 24/08/2026 04:04
- 1.3 — Restored “plausible” qualifier: Changed [time_3_sub] from “No measurable change by 12 months has no explanation other than non-response” to “No measurable change by 12 months has no plausible explanation other than non-response”, matching the ER’s wording.
Issues 24/08/2026 03:58
- 4.5 — Content overruns one A4 page: Visible body content totals ~4,940 characters, which at the template’s own A4 print geometry stacks to roughly 1,900 px against a ~1,032 px content box; the Key Interactions gate (lines 579–589), the Monitoring table (lines 635–722) and the Qualitative Assessment list (lines 738–753) carry the ER’s wording at near-full length rather than condensed to the per-section budget.
- 2.5 — Prescriptive wording in Protocol: [action_3_value] at line 478 reads “Twice daily preferred”, stating a recommendation, where the ER only reports that the short residence time “argues for twice-daily application over a single larger dose” (ER line 318).
Fixes 24/08/2026 03:58
- 4.5 — Page-budget condensation across sections: Visible body content cut from ~4,940 to ~4,447 characters by tightening the Protocol and Time-to-Effect sub-lines, the Contraindications and Key Interactions gate items, the Monitoring table cells and cadence, the low-tier Risks line and the Qualitative Assessment list. All six contraindications, nine interactions, eight biomarkers and five qualitative markers were retained.
- 2.5 — Prescriptive wording in Protocol: [action_3_value] changed from “Twice daily preferred” to “Twice daily over one dose”, removing the recommendation and matching the ER’s neutral comparison of split against single dosing.
Issues 24/08/2026 03:49
- 4.3 — Time-to-effect label abbreviated: [time_1_label] at QRS L495 reads “Closure of chronic skin wounds”, dropping “Accelerated” from the ER benefit heading “Accelerated Closure of Chronic Skin Wounds” (ER L139), which the QRS itself reproduces in full in [benefits_medium] at L546.
Fixes 24/08/2026 03:49
- 4.3 — Time-to-effect label abbreviated: Restored the full ER label in [time_1_label], changing “Closure of chronic skin wounds” to “Accelerated closure of chronic skin wounds” to match the ER benefit heading and the wording already used in [benefits_medium].
Issues 24/08/2026 03:44
- 1.3 — At-a-glance overstates ER hedges: [at_a_glance] (lines 434-437) converts the ER’s “No controlled study has measured hair count, thickness or coverage in people” into “no human study has measured hair count or thickness”, and converts “far larger than the size that passes through intact skin unaided … whether a serum delivers a meaningful amount is unknown” into the categorical “far too large to cross intact skin”.
- 11.2 — Time-to-effect order inverts benefit tiers: [time_1]/[time_2] carry the Speculative-tier hair timings while [time_3] (lines 523-532) carries chronic wound closure, the ER’s only Medium-tier benefit, so the sets are not ordered by magnitude of the related benefit.
Fixes 24/08/2026 03:44
- 1.3 — At-a-glance hedges restored: Rewrote [at_a_glance] to match the ER’s cautious phrasing — “no human study has measured hair count or thickness” became “no controlled study in people has measured hair count or thickness”, and “far too large to cross intact skin” became “far larger than what passes through intact skin” (59 words, still under the 60-word cap).
- 11.2 — Time-to-effect reordered by benefit tier: Moved chronic wound closure (the ER’s only Medium-tier benefit) into [time_1] and shifted the Speculative-tier hair timings to [time_2] (3–4 months, visible change) and [time_3] (12 months, fair assessment).